Business Wire

Stoli® Vodka Says It “Loud and Clear” with New Global Advertising Campaign

Share

Stoli® Vodka, the original premium vodka with uncompromising quality for the past 80 years, announced today the launch of their new global advertising campaign, “Loud and Clear.” The provocative new campaign features work from award-winning artists like composer Hans Zimmer, Lorne Balfe and director Rachel Morrison. The campaign takes a 360-approach, incorporating television, digital, social and print to reveal Stoli®’s unapologetic message – whatever drives you, make it bold, make it last, make it loud and clear.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180516006326/en/

Famed photographer Rankin led the print creative for Stoli Vodka's "whatever drives you, make it lou ...

Famed photographer Rankin led the print creative for Stoli Vodka's "whatever drives you, make it loud and clear" advertising campaign, which the brand introduced earlier this week.

The release of the “Loud and Clear” campaign demonstrates Stoli’s unwavering presence in the spirits industry, while differentiating itself as the real deal in today’s vodka sea of sameness. Shot in Ukraine, each creative spot showcases real people celebrating their unique identities and what drives them. The footage makes it “Loud and Clear” that they are fully embracing their style, passions and beliefs with conviction.

“Our new advertising campaign truly captures the boldness and clarity of Stoli,” said Hugues Pietrini, Global President & CEO of Stoli® Group. “With an 80-year history in the spirits category, we are proud of our brand identity and values and want our fans to feel the same. We encourage them to ‘make it loud and clear’ that they are embracing and broadcasting their true selves without inhibition.”

Developed with FF New York, the global creative agency founded by Fred & Farid, “Loud and Clear” boasts an impressive lineup of award-winning creative talent who contributed to the campaign. “Loud and Clear” features music from the Oscar-winning composer, Hans Zimmer, and Emmy/BAFTA-nominated composer Lorne Balfe, which elevates the drama and emotion in the piece.

Oscar Nominee Rachel Morrison served as the campaign’s director of photography on the video, which was shot by directors “We are From LA”. The print creative was shot by esteemed photographer Rankin in London and features the designs of graphic artist Tyrsa, who created a brand new font, Stoli Brush, for all of the print ads. The font will be made accessible for Stoli fans and consumers alike to download and use for free.

“A new campaign for Stoli needed both a bold, new positioning from the brand and the right creative community to bring it to life,” said Fred & Farid, founders of FF. “As such, we worked with distinctive, visionary artists who are uncompromising in their values. The work of Mr. Zimmer, Mr. Balfe and Ms. Morrison were an incredible fit for the spirit of the brand.”

For more information, visit www.stoli.com or follow Stoli Vodka on Instagram @Stoli, on Facebook at www.facebook.com/stoli and on Twitter @Stoli.

About Stoli Group ®

Part of SPI Group – one of the world's leading premium spirits businesses – Stoli Group was established in 2013 as the division responsible for the management, distribution and marketing of SPI's global spirit portfolio.

Contact information

Stoli Group
Alison Walsh, +1-917-301-2962
awalsh@stoli.com
or
MWW PR
Leslie Norden, +1-323-798-3925
lnorden@mww.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 17:59:00 CESTPress release

Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who

Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 13:05:00 CESTPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar

Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 12:30:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include

Schlumberger Announces Second-Quarter 2019 Results19.7.2019 11:00:00 CESTPress release

Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente

Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 10:46:00 CESTPress release

Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe

Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 10:00:00 CESTPress release

Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail fluke-info@fluke.com or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu